PharmaSphere: Regulatory Frameworks and Product Pipelines in the Global Biosimilars Market

Publisher Name :
Date: 30-Jun-2014
No. of pages: 173
Inquire Before Buying

GlobalData's report, "PharmaSphere: Regulatory Frameworks and Product Pipelines in the Global Biosimilars Market", provides strategic analysis of the global biosimilars industry. It discusses key market trends, regulatory requirements in various markets, recent deals activity and trends, as well as describes the operations strategy of these companies. Furthermore, it includes a geographical segmentation of various markets including the EU and US, as well as emerging markets such as India providing in-depth analysis of these markets' regulatory framework, key domestic players and their biosimilar pipelines, and strategic outlook.

Throughout the report, GlobalData's analysts provide you with expert insight, expanding on each strategy and factor discussed, with the aim of providing you with the tools needed for making informed business decisions.

Highlights

About the Report

GlobalData's PharmaSphere: Regulatory Frameworks and Product Pipelines in the Global Biosimilars Market report is an essential source of information and analysis on the global biosimilars industry. Using detailed company data, financial analysis, corporate strategy, and market trends analysis, GlobalData provides in-depth analysis of the current and future growth drivers of the biosimilars industry. The report discusses the various regulatory frameworks under which biosimilars are currently reviewed and regulated. Furthermore, it discusses the key factors shaping and driving the biosimilars business, and provides insights on the competitive landscape and emerging strategies expected to significantly influence the market positions of companies currently involved in the development and commercialization of biosimilars.

Key Questions Answered

What are the drivers of the global biosimilars industry?


  • Who are the top players involved in the development of biosimilars in the developed markets of Europe and the US, as well as in emerging markets, including India and China?

  • What are the major barriers to entry into the biosimilars industry?

  • What specific strategies are companies utilizing to combat some of the challenges currently facing the development of the global biosimilars industry?

  • What is the current state of biosimilars regulation in the EU, US, Japan, India, China, and South Korea?


Scope

  • The report provides analysis of the key drivers and trends shaping the global biosimilars industry.

  • The report discusses the biosimilar regulatory landscape of various markets including developed markets of the US and EU, as well as emerging markets such as China and India. Furthermore, it identifies key domestic players in the various markets discussed and provides analysis of their strategy, manufacturing capacity, and clinical pipeline.

  • The report contains expert insights on the corporate strategies of current and prospective players in the global biosimilars industry.

  • The report contains a special case study on Teva Pharmaceutical Industries' biosimilars business, including an in-depth SWOT analysis of the company.


Reasons to buy

  • Understand the frameworks under which biosimilars are currently being reviewed and regulated across various developed and emerging markets

  • Identify the key domestic players in various biosimilar markets, including South Korea, Japan and emerging markets such as India and China

  • Understand the key drivers and trends in the global biosimilars industry

  • Analyze and track the strategies that companies are using to enter and/or strengthen their position in the rapidly evolving biosimilars industry, as well as efforts being made by innovator companies like Amgen to protect their market position

  • Use this information as an independent source for your due diligence and transaction strategy

PharmaSphere: Regulatory Frameworks and Product Pipelines in the Global Biosimilars Market

Table of Contents

1 Table of Contents 7
1.1 List of Tables 12
1.2 List of Figures 14

2 Introduction 15
2.1 Report Scope 15
2.2 Upcoming Related Reports 16
2.3 Recently Published Reports 17

3 Market Overview 18
3.1 Biologics: An Expensive Necessity 18
3.2 Historical Branded Biologic Sales and Forecast 20
3.3 A Trickling Biologics Pipeline 22
3.4 Why Biosimilars? 22
3.4.1 Rising Healthcare Expenditures 23
3.4.2 The Need to Broaden Healthcare Coverage and Drive Macroeconomic Growth 23
3.5 Biosimilars: Not an ?Easy' Venture 23
3.5.1 Complex Manufacturing Processes 24
3.5.2 Rigorous Regulatory Requirements 25
3.5.3 No Automatic Substitution 26
3.6 Clinical Trials Landscape 26

4 Biosimilar Deals Trends 31
4.1 Highlighted Deals 32
4.1.1 Baxter International and Coherus Biosciences Announce Biosimilars Collaboration 35
4.1.2 Genor BioPharma and BioCND Form mAb Partnership for International Markets 37
4.1.3 Pfenex Forms JV with Agila Biotech 38
4.1.4 Viropro and Oncobiologics Sign Emerging Markets Biosimilars Deal 39
4.1.5 Samsung Bioepis and Merck Expand Biosimilars Development Agreement 41
4.2 Additional Deals 44

5 Biosimilars Regulation 45
5.1 Biosimilars: Different Names, Common Themes 45
5.2 WHO's Guidance on SBPs 45

6 Biosimilars in the US 47
6.1 Overview 47
6.2 The US' Evolving Regulatory Framework for Biosimilars 47
6.2.1 Big Pharma's Adverse Reaction to Section 505(b)(2) 48
6.2.2 The Patient Protection and Affordable Care Act 50
6.2.3 Recent Guidances on Biosimilars by the FDA 51
6.3 Mixed Feelings among Stakeholders as US States Embrace Biosimilar Substitution 55
6.4 Key Players and Pipelines 56
6.4.1 Hospira 56
6.4.2 Actavis 60
6.4.3 Pfizer 62
6.5 Biosimilars in the US: Market Outlook 64
6.5.1 Efforts to Establish a Regulatory Framework Favors the Development of the Industry 64
6.5.2 Increasing Healthcare Expenditures Will Drive Biosimilars Substitution 65
6.5.3 Large Biotechs and Pharmas Will Aggressively Defend their US Market Share 65
6.5.4 Patent Expirations of Blockbuster Biologics Will Encourage Biosimilar Developers 66

7 Biosimilars in Europe 67
7.1 Overview 67
7.2 EU Approved Biosimilars 67
7.3 Guidelines for Biosimilars Development in the EU 70
7.3.1 Sandoz Triggered the Development of Guidelines for Biosimilars in Europe 70
7.3.2 Applicable Guidance Documents on Biosimilars in Europe 71
7.3.3 Non-Clinical Data and Clinical Studies 72
7.4 Key Players and Pipelines 73
7.4.1 Sandoz 73
7.4.2 Stada Arzneimittel 76
7.4.3 Gedeon Richter 78
7.5 Biosimilars in Europe: Market Outlook 80
7.5.1 Financial Austerity Measures Will Further Drive the Uptake of Biosimilars 80
7.5.2 Companies Will Use the EU Biosimilars Market as a Springboard into the US Market 82

8 Biosimilars in Japan 83
8.1 Overview 83
8.2 Regulatory Framework 83
8.2.1 Organizational Structure 83
8.2.2 Biosimilars Review Process 84
8.2.3 Regulatory Guidelines 85
8.3 Key Players and Pipelines 87
8.3.1 Kyowa Hakko Kirin Co. Ltd. 87
8.3.2 JCR Pharmaceuticals 90
8.4 Biosimilars in Japan: Market Outlook 92
8.4.1 Cost Containment Measures Will Drive Biosimilars Development 92
8.4.2 CMOs Will Leverage Existing Capabilities to Enter Biosimilars Space 92

9 Biosimilars in India 93
9.1 Gradual Transition from a Semi-Regulated to a Regulated Market 93
9.2 Marketed Biosimilars in India 93
9.3 Regulatory Framework for Biosimilars in India 97
9.3.1 Guidelines on Similar Biologics, 2012 101
9.4 Key Players and Pipelines 102
9.4.1 Biocon 102
9.4.2 Dr. Reddy's Laboratories 106
9.4.3 Ranbaxy Laboratories 108
9.4.4 Reliance Life Sciences 111
9.4.5 Cipla 112
9.5 India Biosimilars Market Outlook 114
9.5.1 Recent Biosimilar Guidelines Will Not Guarantee Approval by Regulators 114
9.5.2 Expertise in Generics Will Encourage Biosimilars Development 115
9.5.3 EU-India Free Trade Agreement Could Open Up Access to the European Market 115

10 Biosimilars in South Korea 117
10.1 Overview 117
10.2 Government Initiatives Aiding the Development of Biosimilars 119
10.3 Joint Ventures and Collaborations Enable Leveraging of Capabilities 120
10.4 Lack of Biologics' Market Exclusivity Decelerates Time-to-Market 121
10.5 Regulatory Framework for Biosimilars 121
10.5.1 Extrapolation of Indications 123
10.6 Key Players and Pipelines 123
10.6.1 Celltrion 124
10.6.2 Hanwha Chemical 127
10.6.3 Samsung Bioepis 129
10.6.4 LG Life Sciences 129
10.7 Biosimilars in South Korea: Market Outlook 132
10.7.1 Government's Initiatives Look Poised to Spur the Local Biosimilars Industry 132
10.7.2 Budding Pipeline Signals Boom for the Biosimilars Industry 133

11 Biosimilars in China 134
11.1 Overview 134
11.1.1 Soaring Healthcare Expenditures in China Drive Need for Cheaper Therapeutics 134
11.1.2 Biosimilars and Reimbursement 135
11.1.3 An Intellectual Property Loophole 136
11.2 Regulatory Framework for Biosimilars in China 136
11.3 Key Players and Pipelines 138
11.3.1 3SBio 138
11.3.2 Shandong Kexing Bioproducts 140
11.4 Biosimilars in China: Market Outlook 141
11.4.1 Ongoing Reform Will Boost Biosimilars Industry 141
11.4.2 Increase in Healthcare Access Bodes Well for Biosimilars in China 141
11.4.3 Collaborations between Multinationals and Domestic Companies Will Continue 142

12 Case Study: Teva Pharmaceutical Industries 143
12.1 Business Overview 143
12.2 Biosimilars at Teva 143
12.3 Product Portfolio/Pipeline 144
12.4 Company SWOT Analysis 145
12.4.1 Strengths 145
12.4.2 Weaknesses 147
12.4.3 Opportunities 147
12.4.4 Threats 149

13 Strategic Outlook 151
13.1 Patent Expiries Will Continually Fuel Biosimilars Development 151
13.2 Flurry of Regulatory and Legislative Activities Bodes Well for Biosimilars 151
13.3 Extensive Capabilities Needed Will Serve as a Barrier to Entry in the Near to Mid-term 152
13.4 EU-India FTA Will Significantly Benefit European and Indian Biosimilars Companies 153
13.5 Cost-containment Measures Are Expected to Drive Biosimilars Substitution 154

14 Appendix 156
14.1 Bibliography 156
14.2 Abbreviations 165
14.3 Research Methodology 168
14.3.1 Coverage 168
14.3.2 Secondary Research 169
14.4 About the Author 170
14.4.1 Adam Dion, Industry Analyst 170
14.5 Director of Healthcare Industry Dynamics 170
14.6 Global Head of Healthcare 171
14.7 About the Industry Dynamics Team 171
14.8 About GlobalData 172
14.9 Disclosure Information 172
14.10 Disclaimer 172

List of Tables

Table 1: Major Biologic Products 19
Table 2: Ongoing Biosimilar Clinical Trials 27
Table 3: Overview of Biosimilars Deals Analyzed in This Report 33
Table 4: Baxter International and Coherus Biosciences Biosimilars Collaboration 36
Table 5: Genor BioPharma and BioCND Licensing Deal 37
Table 6: Pfenex's JV with Agila Biotech 38
Table 7: Viropro and Oncobiologics' Biosimilars Deal 40
Table 8: Samsung Bioepis and Merck Sign Biosimilars Development Agreement 42
Table 9: Biosimilar Evaluation Requirements - WHO, South Korea, EU, and Japan 46
Table 10: Hospira: Marketed Biosimilars 58
Table 11: Hospira: Biosimilars Developmental Pipeline 59
Table 12: Actavis' Biosimilars Pipeline 62
Table 13: Pfizer's Biosimilars Pipeline 64
Table 14: Authorized Biosimilars in the EU 69
Table 15: Sandoz: Marketed Biosimilars 74
Table 16: Sandoz: Pipeline of Developmental Biosimilars 75
Table 17: Stada Arzneimittel's Current Biosimilars Pipeline 78
Table 18: Gedeon Richter's Current Biosimilars Pipeline 80
Table 19: Kyowa Hakko Kirin's Late-stage Biologics Pipeline 89
Table 20: JCR Pharmaceuticals' Product Pipeline 91
Table 21: Currently Marketed Biosimilars in India 95
Table 22: Guidelines Applicable to the Research, Development and Marketing of Biosimilars in India 102
Table 23: Biocon: Marketed Biologics 105
Table 24: Biocon: Current Developmental Biologics Pipeline 106
Table 25: Dr. Reddy's: Marketed Biosimilars 108
Table 26: Ranbaxy's Current Biosimilars Pipeline 110
Table 27: Reliance Life Sciences: Marketed Biosimilars 112
Table 28: Reliance Life Sciences: Pipeline Biosimilars 112
Table 29: Cipla Combined Annual Manufacturing Capacities 114
Table 30: Some Biosimilars in Development by South Korean Drug Companies 118
Table 31: Deals in the South Korean Biosimilars Industry 120
Table 32: Celltrion Product Pipeline 125
Table 33: Hanwha Chemical's Current Product Pipeline 128
Table 34: LG Life Sciences' Current Product Pipeline 132
Table 35: 3SBio's Clinical Pipeline 140
Table 36: Teva Pharmaceutical Industries: Marketed and Developmental Biosimilars 145

List of Figures

Figure 1: Historical Sales of Branded Biologics, 2008-2013 and Forecast to 2019 21
Figure 2: New Biologics* Approvals by the FDA, 2006-2013 22
Figure 3: Groups of Companies Involved in Biosimilars Development 25
Figure 4: Trend in Deals in the Biosimilars Industry, 2007-2013 32
Figure 5: FDA-Recommended Stepwise Approach for Biosimilars' Development in the US 52
Figure 6: Current Guidelines on Biosimilars Regulation in the EU 71
Figure 7: Novartis' Capabilities being Leveraged by Sandoz 76
Figure 8: Public Debt and Budget Deficit-to-GDP Ratios in the Eurozone, 2013 81
Figure 9: PMDA's Current Organizational Chart 84
Figure 10: Review Process for Biosimilars in Japan 85
Figure 11: Indian Regulatory Pathway for Indigenously Manufactured Biologics 99
Figure 12: Indian Regulatory Pathway for Imported Biologics 100
Figure 13: South Korean's Three-tiered Regulatory System for Biosimilars 122
Figure 14: Celltrion Product Pipeline by Therapeutic Area 126
Figure 15: LG Life Sciences' R&D Investment, 2009-2013 (Estimated) 131
Figure 16: Total and Government Healthcare Expenditures* in China, 2001-2011 135
Figure 17: Application and Approval Procedure for Pharmaceuticals in China 137
Figure 18: Teva's Global Biosimilars Operation: A Recipe for Success 144
Figure 19: Teva Generics Sales in US vs. Rest-of-World (ROW), 2009-2012 149
Figure 20: Teva Pharmaceuticals: SWOT Analysis 150
Figure 21: Capabilities Needed for Biosimilars Development 153
Figure 22: US Healthcare Expenditure and GDP, 2001-2013 155

  • Global Luxury Apparels Market To Do Well Owing To Numerous International Brands
    The global luxury apparels market is fired by the intensifying number of fashion marques and many designers getting wide-ranging clienteles in the form of cost-effective products. The global luxury apparels market was at US$1, 8842.69 million in 2015 and is forecast to reach US$60,793.7 million by the end of 2024. This segment of luxury goods [...]
  • Global Health and Wellness Market Boosted By Organic Products and Wearables
    Healthcare has constantly been a profitable area where buyers spend belligerently. But now, with increasing disposable earnings amid the city population and ground-breaking approaches and innovative products being developed, the overall health and wellness market is estimated for a healthy prospect. The health and wellness market is presently very dynamic owing to growing alertness amongst [...]
  • Increasing New Outlets And Striking Offers To Drive Global Pizza Market
    The global pizza market is predicted to grow at a steady CAGR of about 3% by 2020. Pizza has been gaining massive acceptance globally in the last few years. Consequently, the global pizza market is anticipated to observer considerable progress in the coming years. The growing number of pizzerias is one of the major elements [...]
  • Healthy Diet Demand In Developed Economies To Boost Nutraceuticals
    As customers scuffle to keep up with the frantic lifestyles, the necessity for healthy nutrition rises owing to dearth of time to spend on laborious exercises.  Customers are shifting their attention to swift and healthy food behaviours. Increase in intake of beverages and functional food has offered makers of nutraceuticals with money-spinning prospects to benefit [...]
  • World Economic Forum Unveils Top 10 Emerging Technologies of 2016
    The World Economic Forum (WEF) and Scientific American lately unveiled the major technological innovation list of the top ten emerging technologies of 2016. This list emphasizes on the technological developments which have the supremacy to transform industries, protect the planet, and improve lives. It also presents an opening to discuss any societal, human, economic or [...]
  • Biosimilar (Insulin) - Competitive Landscape and Market & Pipeline Analysis, 2016
    Published: 01-Nov-2016        Price: US 1450 Onwards        Pages: 79
    DelveInsight's, "Biosimilar (Insulin) - Competitive Landscape and Market & Pipeline Analysis, 2016" discusses the global insulin biosimilar industry. Report analyzes that Insulin and Insulin Biosimilars holds a future Scope and potential in the market. It highlights the market trends, regulatory requirements for US and EU and key domestic players. Report provides an insight on Insulin Biosimilars that are under development for Type 1 and Type 2 Diabetes with an in......
  • China Biologics and Biosimilars Market Research Report 2016
    Published: 26-Oct-2016        Price: US 3200 Onwards        Pages: 123
    Notes: Sales, means the sales volume of Biologics and Biosimilars Revenue, means the sales value of Biologics and Biosimilars This report studies Biologics and Biosimilars in China market, focuses on the top players in China market, with capacity, production, price, revenue and market share for each manufacturer, covering - Pfizer - Roche - Amgen - AbbVie - Sanofi - Johnson & Johnson - Novo Nordisk - Novartis......
  • China Biosimilars Market Research Report 2016
    Published: 25-Oct-2016        Price: US 3200 Onwards        Pages: 117
    Notes: Sales, means the sales volume of Laser Capture Microdissection Revenue, means the sales value of Laser Capture Microdissection This report studies Biosimilars in China market, focuses on the top players in China market, with capacity, production, price, revenue and market share for each manufacturer, covering - Sandoz International GmbH (Germany) - Hospira, Inc. (U.S.) - Teva Pharmaceutical Industries Ltd. (Israel) - Dr. Reddy's Lab......
  • China Biosimilar Drug Market by Manufacturers, Type and Application, Forecast to 2021
    Published: 04-Oct-2016        Price: US 4480 Onwards        Pages: 101
    Biosimilar drug is medicine made using a living system, and historically this was often an animal. Most products being developed as biosimilar drug are recombinant proteins, or proteins derived from genetically engineered DNA. In this report is a biologic defined as proteins, peptides, hormones or antibodys drugs production by bio-engineered technology, but does not include a vaccine. Scope of the Report: This report focuses on the Biosimilar Drug in China market. This repo......
  • Global Biosimilars Market and Forecast (By Product Type, Applications, Country Wise and Companies) to 2021 and Biosimilars Approved and Pipeline Analysis
    Published: 03-Oct-2016        Price: US 1350 Onwards        Pages: 177
    The biosimilars are poised to capture an unprecedented position in the biopharmaceutical industry driven by an increased extent of adoption and growing investment and deal making activity globally. The global biosimilars market is predicted to cross US$ 25 Billion mark by 2020.  With the continuous increasing demand for biologics, manufacturers are looking for novel strategies that will help them attain maximum returns on investment. Biosimilars are seen as the key weapon to curbing soar......
  • Global mAb Biosimilars Market 2016-2020
    Published: 23-Sep-2016        Price: US 2500 Onwards        Pages: 103
    Biosimilars or follow-on biologics are generic versions of the biopharmaceutical products. These are developed following the patent expiry of an original molecule. Biosimilars have the same biological properties as original drugs and target the same diseases. They have many similarities but are not identical to the reference biopharmaceutical product. The analysts forecast spending on the global monoclonal antibody (mAb) biosimilars market to grow at a CAGR of more than 57% durin......
  • Global Biologics and Biosimilars Market Professional Survey Report 2016
    Published: 08-Aug-2016        Price: US 3500 Onwards        Pages: 110
    Notes: Production, means the output of Biologics and Biosimilars Revenue, means the sales value of Biologics and Biosimilars This report studies Biologics and Biosimilars in Global market, especially in North America, Europe, China, Japan, Southeast Asia and India, with production, revenue, consumption, import and export in these regions, from 2011 to 2015, and forecast to 2021. This report focuses on top manufacturers in global market, with production......
  • United States Adalimumab Biosimilar Industry 2016 Market Research Report
    Published: 02-Aug-2016        Price: US 3800 Onwards        Pages: 130
    The United States Adalimumab Biosimilar Industry 2016 Market Research Report is a professional and in-depth study on the current state of the Adalimumab Biosimilar industry. The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The Adalimumab Biosimilar market analysis is provided for the United States markets including development trends, competitive landscape analysis, and key regions development s......
  • Global Biosimilars Market 2016-2020
    Published: 01-Aug-2016        Price: US 2500 Onwards        Pages: 152
    Biosimilars are defined as the follow-on versions of original biological medicines. These are separately developed after the patent protecting the original product has expired. Biosimilars are intended to have the same MOA as original biological drugs and are designed to treat the same diseases as the innovator's product. They have many similarities, but are not identical to, the reference biopharmaceutical product. The analyst forecast global biosimilars market to grow at a CAGR of 5......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs